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Volatile aldehydes are enriched in esophageal adenocarcinoma (EAC) patients’ breath and
could improve early diagnosis, however the mechanisms of their production are unknown.
Here, we show that weak aldehyde detoxification characterizes EAC, which is sufficient to
cause endogenous aldehyde accumulation in vitro. Two aldehyde groups are significantly
enriched in EAC biopsies and adjacent tissue: (i) short-chain alkanals, and (ii) medium-chain
alkanals, including decanal. The short-chain alkanals form DNA-adducts, which demonstrates
genotoxicity and confirms inadequate detoxification. Metformin, a putative aldehyde sca-
venger, reduces this toxicity. Tissue and breath concentrations of the medium-chain alkanal
decanal are correlated, and increased decanal is linked to reduced ALDH3A2 expression, TP53
deletion, and adverse clinical features. Thus, we present a model for increased exhaled
aldehydes based on endogenous accumulation from reduced detoxification, which also
causes therapeutically actionable genotoxicity. These results support EAC early diagnosis
trials using exhaled aldehyde analysis.
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A lerting symptoms of esophageal adenocarcinoma (EAC)typically indicate advanced and incurable disease, whereasfeatures of early stage disease, such as heartburn, are non-
specific1,2. Thus, despite the availability of safe and effective
treatments for early EAC, prognosis remains poor with a 5-year
survival of 14%3. The gold standard diagnostic test is endoscopy,
which is invasive, uncomfortable, and expensive. Additionally,
this cannot be offered to every patient with non-specific symp-
toms, as these are extremely common. New diagnostic adjuncts
are needed to triage patients with non-specific symptoms to
receive an endoscopy, especially as the EAC incidence in Western
countries has risen sharply in recent decades and is not projected
to fall4.
Exhaled aldehydes have been consistently demonstrated to
be enriched in EAC patients5,6, and could form the basis of a
non-invasive, primary care-based, triage test for patients with
non-specific upper gastrointestinal symptoms. However, the
mechanisms underlying these biomarkers’ production remain
unknown. Molecular studies have identified that endogenous
aldehydes are potent mediators of malignant transformation7,8.
These carbonyls can react with base-pairing amines in
DNA at ambient conditions, and formaldehyde and acet-
aldehyde among others are designated carcinogens9. For eso-
phageal squamous cancers, inactivating variants in ALDH2
convey predisposing risk10. For EAC and the precursor eso-
phageal intestinal metaplasia (Barrett’s esophagus), glutathione
defenses—an auxiliary mechanism of aldehyde detoxification—
may be depleted11,12. Together, this suggests the esophagus is
exposed to aldehyde stress, and that glandular esophageal cells
may be vulnerable to this stress. However, esophageal aldehyde
biochemistry has not been described.
In this study, we investigate whether exhaled EAC bio-
markers could be explained by corresponding changes in the
EAC microenvironment, and aim to identify the molecular
mechanisms underpinning these changes. We show that short-
chain genotoxic alkanals and also medium-chain alkanals are
specifically enriched in EAC and associated tissues, on a genetic
background of reduced aldehyde detoxification. This metabolic
deregulation generates genotoxicity and correlates with exhaled
biomarkers, and thus has implications for ongoing research in
early EAC detection.
Results
Reduced aldehyde detoxification characterizes glandular tis-
sues in the esophagus. We first asked whether a cell-autonomous
mechanism could contribute to exhaled biomarkers, so we began
by searching for thematic differences in metabolic gene expres-
sion between EAC and relevant control tissue in archived tran-
scriptomic datasets. Compared to EAC, squamous mucosa for
healthy controls (SqN) was defined by a strong aldehyde oxida-
tion theme (Fig. 1a, b and Supplementary Data 3), suggesting
reduced aldehyde defense in EAC tissue. Ingenuity Pathway
Analysis identified an analogous leading phenotype (Supple-
mentary Fig. 1a). The EAC precursor Barrett’s metaplasia also
had differences in redox gene expression (Supplementary Data 3),
in keeping with a previous report of disengaged glutathione
metabolism11. A meta-analysis of the public datasets at a single
gene level identified ALDH1A3, -3A1, -3A2, -4A1, and -9A1 as
consistently under-expressed in EAC compared to normal eso-
phageal squamous mucosa (Supplementary Fig. 1b, ALDH3B2 is
a pseudogene). We validated these observations experimentally
using quantitative polymerase chain reaction (qPCR) on paired
endoscopic biopsies from 67 patients (Fig. 1c). These data com-
plement those from epidemiological and genomic studies which
link deactivating ALDH variants to esophageal malignancies10,13.
Importantly, these five aldehyde dehydrogenase isoenzymes show
specificity to products of lipid peroxidation, a major source of
endogenous aldehydes14.
Further assessments suggested that ALDH3A2 was expressed in
BAR but not EAC, whereas other ALDH genes were under-
expressed in both BAR and EAC (Supplementary Fig. 1b, c). To
explore this, we used immunohistochemistry, as non-dysplastic
Barrett’s epithelium is a monolayer and prone to contamination
in bulk tissue preparations (see Fig. 1d, e). ALDH3A1 was
strongly expressed in SqT but weakly in Barrett’s tissue and EAC
(Fig. 1d, f). In contrast, its 17p co-localizing homolog ALDH3A2
was expressed in all SqT, >90% of Barrett’s metaplasia and
dysplasia, and 21% of EAC (Fig. 1e, f). Subgroup analysis by
clinicopathologic features revealed associations of reduced
ALDH3A2 with advanced stage and poorly differentiated disease
(Supplementary Data 4). Thus, low expression of ALDH3A1
was common to all esophageal glandular epithelia, whereas loss of
ALDH3A2 was linked to malignant transformation and progres-
sion. These genes’ products show particular affinity to medium
and fatty alkanals14, and both genes are not expressed in most
EAC cases.
Next we tested whether squamous and EAC in vitro models
shared these phenotypes. Good commercial esophageal squamous
models are lacking15, so we validated a new technique for culturing
normal esophageal keratinocytes in vitro using the rho kinase
inhibition/irradiated fibroblast co-culture method16. These cells
strongly expressed squamous cytokeratins, p63, and E-cadherin,
and were depleted for vimentin (Supplementary Fig. 1d). Compared
to commercial EAC and Barrett’s cell lines, keratinocyte cultures
had robust expression of all tested ALDH genes, and lower
concentrations of DNA double-strand break marker phosphory-
lated γ-H2AX (Supplementary Fig. 1e).
Recent work suggests that ALDH-mediated detoxification is the
primary means of preventing endogenous aldehyde accumulation7.
To test whether the observed reduced ALDH expression could
cause aldehyde accumulation in an EAC-relevant system, we
blocked ALDH pharmacologically and genetically, and measured
metabolic phenotypes. To do this, we developed a targeted ultra-
performance liquid chromatography tandem mass spectrometry
(UPLC-MS/MS) method to quantify 42 carbonyls (aldehydes and
ketones) in tissue and liquid samples, updating the classical
dinitrophenylhydrazine (DNPH) approach (see “Methods”). The
method overcame the range in polarity, volatility and reactivity
from light to fatty acyls, covered a broad range of biology-relevant
carbonyls, and allowed unambiguous identification of DNPH-
reactive isomers/isobars such as alkanals, ketones, and dialdehydes
(e.g. acetone, propanal, glyoxal, formula mass= 58). There is
metabolic redundancy between the 19 ALDH isoenzymes14, so we
initially chose diethylaminobenzaldehyde-mediated inhibition,
as this inhibits nearly all of the isoenzymes17. There was dose-
dependent enrichment of measured alkanals in OE33 cells,
suggesting that ALDH inhibition is sufficient to overcome
alternative detoxification mechanisms and cause endogenous
aldehyde accumulation (see Supplementary Fig. 2a). Similar effects
were observed under hypoxic conditions (see Supplementary
Fig. 2b), although aldehyde concentrations subsequently reduce,
implying metabolic adaptation. Combining hypoxia and ALDH
inhibition led to sustained aldehyde increases (see Supplementary
Fig. 2c). These phenotypes were replicated in a second EAC cell line
(Supplementary Fig. 2d–f).
We then used RNA interference to study the contribution of
each differentially expressed ALDH isoenzyme to endogenous
aldehyde metabolism. Silencing individual ALDH isoenzymes in
OE33 cells under normal conditions led to enrichment of
acetaldehyde, nonanal, decanal, and some enals (see Supplemen-
tary Fig. 2g, h). These effects were more pronounced when
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multiple genes were silenced, and led to stabilization of the
genotoxicity marker phosphorylated γ-H2AX (Supplementary
Fig. 2g). Similar metabolic phenotypes were observed on silencing
ALDH in CPD cells (Supplementary Fig. 2i). This confirms that
reduced ALDH activity is sufficient to enrich endogenous
aldehydes in glandular esophageal cell lines; however, loss of
specific isoforms causes subtle effects compared to broader genetic
interference or environmental influences.
Genotoxic and medium-chain aldehydes are enriched in the
adenocarcinoma-bearing esophagus. These results encouraged
us to measure EAC aldehyde concentrations in situ, using parallel
endoscopic samples from the PCR study and the optimized
UPLC-MS/MS method. Metabolic field effects have been descri-
bed in the malignant esophagus18, so we chose four test groups:
adenocarcinoma (EAC), cancer-adjacent squamous epithelium
(SqT), cancer-adjacent Barrett’s metaplasia (BAR), and squamous
epithelium from patients without endoscopic abnormality (SqN)
(see Supplementary Data 5).
In unsupervised multivariate analysis, SqN separated from other
tissue in the first principal component, which explained 47% of the
data (Fig. 2a). EAC tissues were significantly enriched for 20 of 27
of the target aldehydes, compared to SqN (Supplementary Fig. 3).
Correlating aldehyde concentrations in EAC samples revealed
three correlated groups: short-chain, medium-chain and fatty
alkanals (Fig. 2b). The genotoxic aldehydes formaldehyde,
acetaldehyde, and 1-butenal were significantly increased in both
SqT and EAC compared to SqN (Fig. 2c–e), suggesting aldehyde
stress exhibits a field effect in the transformed esophagus. EAC was
also enriched for other genotoxic aldehydes, including glyoxal,
malondialdehyde, and 4-hydroxy-2-nonenal (HNE) (Fig. 2f and
Supplementary Fig. 3).
In contrast, medium-chain alkanals were markedly concen-
trated in EAC compared to SqT and SqN, suggesting cell-
autonomous production (see Fig. 2g–j and Supplementary Fig. 3).
Of particular interest was decanal (SqN vs EAC, relative
difference 1.54, P < 0.05), a consistent EAC biomarker in exhaled
breath studies5,6. There were no significant differences in fatty
alkanal concentrations, despite these metabolites being tightly
correlated. Thus, we selected the genotoxic and medium-chain
groups for further focused study.
Genotoxic aldehydes are present as DNA-adducts and are
therapeutically targetable. To establish whether the genotoxic
aldehydes affect esophageal DNA health, we used a second
UPLC-MS/MS method19 to quantify aldehyde-DNA damage
products in patient tissue. Two purine nucleosides were selected,
which feature base-pairing surfaces covalently distorted by
either acetaldehyde, or a naturally occurring20 HNE derivative
(CrodG and 1N6-εdA, respectively, Fig. 3a). Compared to SqN
and circulating leukocyte DNA, both SqT and EAC isolates were
significantly enriched for both tested DNA damage products
(Fig. 3b). These results complement the tissue-aldehyde series,
verifying aldehyde accumulation in EAC and adjacent tissue.
Given the base-pairing position of these adducts, it also proposes
these aldehydes as potential esophageal mutagens.
Fig. 1 Loss of aldehyde detoxification is conspicuous in esophageal adenocarcinoma. a Geneset enrichment analysis comparing squamous mucosa (SqN,
n= 19) and esophageal adenocarcinoma (EAC, n= 21) samples in GSE26886. Five most significantly enriched Gene Ontology v4.0 genesets in squamous
mucosa. P values calculated by the permutation test in the GSEA analysis. b Enrichment plot of “oxidoreductase (OR) acting on aldehydes” geneset from a.
c Relative expression of candidate ALDH isoenzymes in EAC endoscopic biopsies compared to paired SqT biopsies (n= 67), quantitative reverse
transcriptase polymerase chain reaction (median and 95% confidence interval provided. P values calculated with two-sided Wilcoxon matched-pairs
signed rank test; ALDH1A3 P= 0.0026, all others P < 0.0001). d, e Representative immunostaining for ALDH3A1 (d) and ALDH3A2 (e) in an esophageal
cross-section featuring an adenocarcinoma (bar indicates 5 mm). f Summary of ALDH3A1 and -3A2 immunostaining in cancer-adjacent squamous tissue
(SqT, n= 75), Barrett’s metaplasia (BM, n= 14); Barrett’s dysplasia (BD, n= 12), and EAC (n= 571) drawn from nine UK hospitals. Mean ± SEM provided,
Kruskall–Wallis test with Dunn’s correction **P < 0.01, ****P < 0.0001. Source data are provided in the Source Data file.
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The availability of medications21 which scavenge aldehydes or
promote their detoxification prompted us to explore whether this
biology could be targeted therapeutically. We screened a panel of
agents using a 48 h viability assay in FLO1 cells, and found that
pretreatment with metformin offered a significant survival
advantage following exposure to acetaldehyde (relative absor-
bance 1.27, 95% CI 1.23–1.30, P < 0.0001, Supplementary Fig. 4a).
Metformin is a biguanide with several nucleophilic moieties
capable of addition reactions with reactive carbonyls22, and has
been shown to reduce aldehyde-mediated genotoxicity in
hematological malignancies23. A re-analysis of a previously
published breath dataset6 revealed that diabetics with EAC who
were taking metformin had several significantly reduced alkanals
compared to those not taking metformin (Supplementary
Fig. 4b). Initial experiments revealed that 48-h pretreatment
with pharmacologically relevant concentrations of metformin
could prevent stabilization of phosphorylated γ-H2AX in a panel
of esophageal cell lines, following a 5-h exposure to pathologi-
cally relevant concentrations of formaldehyde or acetaldehyde
(Fig. 3c, d). Further functional assessments of the DNA damage
response indicated that metformin caused a dose-dependent
suppression of dsDNA-mediated ATM/Chk2 signaling in EAC
and Barrett’s cell models (Fig. 3e, f), improved viability at a
range of acetaldehyde concentrations (Supplementary Fig. 4c, d),
and increased intracellular stores of reduced glutathione
(Supplementary Fig. 4e, f). In summary, there is evidence of
Fig. 2 Biopsies of esophageal adenocarcinoma and adjacent squamous tissue samples are enriched for genotoxic and medium-chain aldehydes.
a Principal component analysis (PCA) of esophageal tissue aldehyde profiles measured by UPLC-MS/MS. Squamous tissue from healthy patients (SqN,
n= 32 independent patients), esophageal adenocarcinoma (EAC)-adjacent squamous tissue (SqT, n= 59), EAC-adjacent Barrett’s (BAR, n= 8), and EAC
(n= 59) were compared. b Correlation matrix of aldehydes in EAC tissue samples in a. Scale indicates Pearson’s r. c–l Absolute concentrations of the
indicated aldehydes in the tested tissues. Mean ± SEM provided, Kruskall–Wallis test with Dunn’s correction, *P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001. Source data are provided in the Source Data file.
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aldehyde genotoxicity in EAC, which can be modulated by
metformin in vitro.
Decanal links tissue metabolism to exhaled diagnostic bio-
markers. Next we compared the EAC tissue aldehyde profile to
the breath aldehyde profile for similarities. We first used our
previously published6 biomarker search methodology to identify
metabolic features which independently contributed to a multi-
variable diagnostic model for EAC, based on tissue aldehydes.
A five-metabolite model had an area-under-the-curve of
0.983, indicating excellent discriminatory performance (Fig. 4a).
Decanal was a feature of this model.
Given that the validated diagnostic breath model6 for EAC
contains butanal and decanal, we then checked whether the tissue
and breath concentrations were correlated. To bridge the gap
between the tissue and breath metabolic pools, we also tested
whether the concentration of these aldehydes significantly
differed in the headspace above EAC tissue, compared to normal
healthy mucosa (independent cohort, EAC n= 25, SqN= 25),
using our validated proton transfer reaction time-of-flight mass
spectrometry method (see Supplementary Fig. 5). Tissue
butanal concentration was not discriminatory for EAC, did
not correlate to exhaled butanal, and was not significantly
different in tissue headspace (Fig. 4b–d). In contrast, tissue
decanal concentrations were discriminatory for EAC, were
correlated with exhaled decanal, and were significantly
increased in EAC tissue headspace (Fig. 4e–g). These results
reaffirm decanal as an EAC biomarker, and suggest that exhaled
decanal, but not exhaled butanal, may originate within the
tumor. The tissue headspace analysis also identified enriched
acetaldehyde, hexanal, nonanal, and undecanal from EAC
samples (see Supplementary Fig. 5), which provides cross-
platform validation with the UPLC-MS/MS findings (Fig. 2).
Decanal is prognostic and linked to TP53. Finally we wanted to
understand the mechanism for intra-tumoral decanal production.
ALDH3A1 and -3A2 have activity against medium- and fatty-
alkanals14, and silencing of either enriched nonanal and decanal
concentrations in vitro (Supplementary Fig. 2h, i). Similarly,
ALDH3A1 and -3A2 low EAC tumors were enriched for decanal
and other medium-chain alkanals (Fig. 5a, b), and expression of
those genes inversely correlated to exhaled decanal concentra-
tions (Fig. 5c, d). Thus, in EAC in vivo and in vitro, reduced
ALDH3A1 and -3A2 activity is associated with increased decanal.
In The Cancer Genome Atlas (TCGA) data, reduced
ALDH3A2 expression in EAC was associated with significantly
poorer survival (Supplementary Fig. 6a), a pattern we verified in
the OCCAMS immunophenotyping cohort (n= 360, log-rank
P= 0.0001, Fig. 5e). ALDH3A2 expression loss was also
associated with transformation to invasive disease, and later T-
stage (Fig. 1e–f and Supplementary Data 4). On multivariable
regression, low ALDH3A2 expression independently predicted
death (odds ratio 1.64, 95% CI 1.13–2.39, P= 0.01, Supplemen-
tary Data 6). Similarly, analysis of a previous breath dataset6
linked high exhaled decanal to later T-stage and significantly
poorer survival (Fig. 5f and Supplementary Fig. 6b). Increased
tissue decanal was also associated with poorer overall survival
Fig. 3 Aldehyde DNA damage is present in esophageal adenocarcinoma, which can be reduced in vitro by metformin. a Schematic of deoxyadenosine
and deoxyguanosine adduction by acetaldehyde (C2:0) and epoxy-hydroxynonanal (EHN), respectively, to form CrodG and 1N6-εdA. b CrodG and 1N6-εdA
concentrations in DNA extracts from peripheral leukocytes (n= 9), squamous tissue from healthy patients SqN (n= 5), esophageal adenocarcinoma-
adjacent squamous tissue (SqT, n= 20), and esophageal adenocarcinoma (EAC, n= 19). c, d Western blot analysis of the indicated cell lines pre-treated
with metformin (MET) and exposed to 150 μM formaldehyde or 500 μM acetaldehyde for 5 h. e Schematic of the ATM and ATR-mediated DNA damage
repair f Western blot analysis for DNA damage repair protein phosphorylation in the indicated cell lines pre-treated with metformin and exposed to 500
μM acetaldehyde for 5 h. Mean ± SEM provided for analytical triplicates of biological duplicates or triplicates, two-tailed Mann–Whitney U test or ANOVA,
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All blots are representative of three independent experiments with similar results. Source data are
provided in the Source Data file.
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(Fig. 5g). In summary, both reduced ALDH3A2 and enriched
decanal are associated with EAC progression and poorer survival.
Congenital ALDH3A2 mutations cause Sjogren–Larsson syn-
drome (SLS), a neuro-cutaneous syndrome in which keratinocyte
hyperplasia and fatty alkanal accumulation are features21,24. This
strengthens the argument that ALDH3A2 is metabolically non-
redundant. Given that loss of ALDH3A2 (and enriched decanal)
was associated with EAC progression, whereas ALDH3A1 is
generally suppressed in all glandular esophageal cell types, we then
focused on the regulation of ALDH3A2 as the key mediator of
decanal metabolism in EAC development. In TCGA data, the
regulatory regions of ALDH genes were not commonly mutated or
methylated (Supplementary Fig. 6c). However, in transcriptomic
data, ALDH3A2 expression was most highly correlated with
telomeric neighbors (Supplementary Fig. 6d), and an analysis of
ALDH3A2 expression in The Cancer Cell Line Encyclopedia dataset
showed a positive correlation with copy number (Supplementary
Fig. 6e). Hypothesizing that ALDH3A2 copy influences ALDH3A2
expression in EAC, we first checked for focal or regional copy
change at 17p11 by applying GISTIC25 to TCGA single-nucleotide
polymorphism array data. This suggested that 17p frequently
undergoes whole-arm shallow deletion, affecting both the
ALDH3A1/2 and TP53 loci (Fig. 5h). Chromosome 17p loss-of-
heterozygosity is a common event in transformation to EAC and
conveys poorer prognosis26, and TP53 is the only recurrently
deactivated gene in EAC (>80% cases)27,28. Importantly, in two
public datasets, comparing copy number to expression revealed a
positive correlation for ALDH3A2 but not ALDH3A1 (Supplemen-
tary Fig. 5f–k).
To confirm this experimentally, we sought to compare
ALDH3A2 copy number with expression in the OCCAMS
immunophenotyping cohort (n= 360), using four-color fluores-
cence in situ hybridization (FISH), confocal image acquisition in
three dimensions, and automated image analysis (Fig. 5i). This
uses cell morphology to restrict analysis, and thus minimizes
signal contamination from undissectable normal populations
(e.g., fibroblasts, endothelia, immune cells). Tumors with reduced
ALDH3A2 immunostaining had a significantly reduced
ALDH3A2 copy ratio, although ALDH3A1 copy number had no
effect on ALDH3A1 expression (Fig. 5j). We then tested the
hypothesis that 17p arm deletion involves both TP53 and
ALDH3A2 loci by comparing corresponding FISH signal ratios.
These counts were proportionally related (Fig. 5k), in keeping
with TCGA and ICGC genomic data, which supports the
hypothesis that ALDH3A2 copy loss and reduced expression is
related TP53 copy loss. Given that TP53 inactivation occurs
during progression to high-grade dysplasia or EAC27, this could
explain why ALDH3A2 loss was linked to progression in the
immunophenotyping experiments (Supplementary Datas 4 and
6), although SLS observational studies have not reported
increased EAC incidence21. ALDH3A1 expression was not
affected by copy number aberration, presumably because
glandular cells do not express this gene anyway (Fig. 1d, f and
Supplementary Fig. 1b). In summary, reduced ALDH3A2
expression is associated with 17p copy loss involving TP53, and
inversely related to tissue and exhaled decanal. This effect was
associated with poor clinical prognosis.
Discussion
In this study we investigated how intra-tumoral metabolism
contributes to exhaled diagnostic biomarkers of EAC. We found
suppressed aldehyde oxidation to be an EAC hallmark, consistent
with observations of impaired glutathione-mediated redox
defense in Barrett’s and EAC11, and epidemiological series
which linked inactivating ALDH variants to esophageal
malignancies10,13. In vitro, we show aldehyde oxidation loss to be
sufficient to enrich endogenous aldehydes, in keeping with recent
suggestions that detoxification is the primary means of control-
ling endogenous aldehyde accumulation7. We then demonstrated
increased concentrations of genotoxic and medium-chain alka-
nals in EAC samples and adjacent tissues, which correspond to
clinical series measuring exhaled alkanals in EAC5,6. Finally, we
Fig. 4 Tissue decanal is diagnostic and correlates to exhaled decanal. a Receiver operating characteristic curve for EAC detection using a random
forests multivariable model based on the indicated tissue aldehydes, measured by UPLC-MS/MS. b–g Comparison of tissue and exhaled butanal and
decanal. b, e The receiver operating characteristic curve based on tissue butanal (b) or decanal (e) concentrations as a single biomarker (UPLC-MS/MS
cohort). c, f Correlation of EAC tissue butanal (c) and decanal (f) concentration to the paired exhaled breath concentration (data from Markar et al.6).
P values calculated with a two-tailed Spearman test. d, g Gas-phase concentrations of butanal (d) and decanal (g) in the headspace of healthy squamous
(SqN, n= 24) and esophageal adenocarcinoma (EAC, n= 25) samples measured by proton transfer reaction time-of-flight mass spectrometry. Mean ±
SEM provided with two-tailed Mann–Whitney U test. Source data are provided in the Source Data file.
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show that certain aldehydes contribute to genotoxicity in eso-
phageal tissues, whereas others are linked to key genetic events in
progression, and convey prognostic information. These data
provide a model in which reduced detoxification causes the
accumulation of volatile endogenous aldehydes, and thus a
mechanistic basis for a diagnostic breath test for EAC based on
aldehyde biochemistry. This is of critical importance, as the
incidence of EAC has increased sharply in recent decades, sur-
vival remains poor, and diagnosis at treatable disease stages is
fundamental to improving prognosis.
Our finding that concentrations of aldehyde–nucleotide
adducts correspond to free aldehydes both corroborates this
Fig. 5 ALDH3A2 loss connects decanal to prognosis and TP53. a, b Relative aldehyde concentrations in tissue samples of esophageal adenocarcinoma
(UPLC-MS/MS cohort) divided into ALDH3A1 (a) and ALDH3A2 (b) high or low tumors (n= 24, two equal groups). c, d Correlations of ALDH3A1 (c) and
ALDH3A2 (d) expression (CPKG, copies-per-thousand GAPDH values, n= 27) to paired exhaled decanal concentrations from Markar et al.5. e Overall
survival in the multi-center immunohistochemistry cohort, stratified by ALDH3A2 expression (immunoscore > 1 used as cut-off), log-rank test. Patients
surviving <3 months from surgery were excluded (total included n= 329). f Overall survival for patients with esophageal adenocarcinoma in the previously
published exhaled breath cohort5, dichotomized about the median (n= 47). Patients surviving <3 months were excluded. g Overall survival for patients
with esophageal adenocarcinoma in the present UPLC-MS/MS tissue aldehyde dataset, dichotomized about the median (n= 52). Patients surviving
<3 months were excluded. h GISTIC analysis of single-nucleotide polymorphism array data from The Cancer Genome Atlas (n= 89). Blue indicates shallow
deletion red indicates copy gain. i Representative fluorescent in situ hybridization (FISH) image of EAC, bar indicates 25 μm (false colors used). j ALDH3A1/
2 FISH signal counts compared to ALDH3A1 and ALDH3A2 expression (cut-off immunoscore >1 used, n= 145, P= 0.0135 for ALDH3A2). k Correlation of
TP53 FISH signals to ALDH3A1/2 FISH signals. One dot= one patient (n= 134). Pearson’s test. Mean ± SEM provided, two-tailed Mann–Whitney U-test
used unless otherwise stated, *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided in the Source Data file.
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model and demonstrates a functional significance. EAC has a
particularly high mutation rate, comprised of unique patterns
representing incompletely explained etiologies27. Our study pro-
poses aldehyde stress as a source of EAC genotoxicity. Gastro-
esophageal acid reflux is a risk factor for EAC29, and low pH
enhances carbonyl-based nucleophilic addition reactions such as
aldehyde–nucleotide adduction. Compared to the stomach, the
esophageal pre-epithelial mucous layer is comparatively thin and
contains no bicarbonate buffer30, and so the lower esophagus may
be particularly vulnerable to pH-facilitated aldehyde toxicity.
Thus, the finding of aldehyde-DNA damage in EAC carries
clinical impact, as ALDH-enhancing and aldehyde-scavenging
agents exist which augment aldehyde detoxification (exemplified
by metformin in this work)31, with potential implications for
chemopreventative strategies in the pre-EAC metaplastic condi-
tion, Barrett’s esophagus.
We found decanal accumulation to be an affiliated metabolic
phenotype of chromosome 17p deletion in EAC, which involves
TP53 deletion. Chromosome 17p loss-of-heterozygosity is asso-
ciated with reduced survival26, as were reduced ALDH3A2 and
increased decanal in this study. This may broaden the clinical
application of exhaled aldehyde testing to EAC prognostication.
Enhanced tumorigenecity from co-deleted TP53 neighbors has
brought 17p arm deletions into focus32, and our results suggest
that ALDH3A2 could provide TP53-independent metabolic
surrogates of this event. In breast cancer, lipid reprogramming
following CKND2-driven chromosome 8p deletion has been
identified33. Given that up to a quarter of a typical cancer genome
involves arm-level copy number aberration34, druggable genetic
driver events may also provide reliable metabolic surrogates
amenable to non-invasive testing, via collateral effects on non-
redundant metabolic genes.
A recent pan-cancer analysis has found that expression of the
ALDH isoenzymes differs greatly between cancers35. A number of
context-specific factors may mediate the net phenotype from
deregulation of an individual ALDH gene, including (i) the
activity of the other ALDH genes, particularly those with over-
lapping specificities, (ii) the redox state, (iii) microenvironmental
factors, including hypoxia and co-factor availability, (iv)
mechanisms of endogenous aldehyde production, and (v) the
activity of collateral detoxification and repair mechanisms, for
example, the DNA damage response. This may explain why
ALDH2 was not significantly different in this study, despite
underactive ALDH2 being associated with ESCC, a different type
of esophageal malignancy10. In addition, increased expression of
ALDH1A1, 1B1, 3A1 and others has been identified in other
malignancies, with inverse associations with survival14,36,37. The
oncogenic function has been attributed to stemness (1A1) or
chemotherapy resistance (3A1), and whether these changes are
causal or reactive is unclear. In this study, ALDH1A3, -3A1, -4A1,
and 9A1 were under-expressed in both Barrett’s epithelium and
EAC, and the genotoxic aldehydes they detoxify were enriched.
This suggests these phenotypes contribute to oncogenesis, and is
in keeping with sequencing evidence of high mutational burden
in both Barrett’s epithelium and EAC27,38. In contrast, ALDH3A2
expression loss was seen in EAC only, possibly as a consequence
of tumor biology (i.e. TP53 copy loss), rather than the cause.
A potential limitation is the finding that decanal is associated
with more advanced disease stage, which is at odds with its
inclusion in a breath test for early cancer detection. However, all
studies demonstrating enriched decanal in EAC have been in UK
cohorts derived from tertiary care centers, which are inherently
enriched for treatable disease. EAC has dismal survival rates
because most patients cannot be offered curative treatment, and
the breath test (five biomarkers, including decanal) can detect
treatable disease stages. In addition, we identified a positive stage
correlation, which confirms this metabolite’s relevance to disease
biology. Changes in exhaled aldehydes and related compounds
have been observed in other cancers39, and how these biomarkers
perform in different disease contexts is a research priority. The
lack of difference in decanal concentration in diabetics taking
metformin is unsurprising as decanal is relatively unreactive,
which further supports its potential as a volatile biomarker.
Another limitation is that the present work aimed to
understand events at a tissue level, rather than unpick the
kinetics of these compounds to exhaled breath. Our previous
work suggested hematological kinetics for fatty acid VOCs40.
For aldehyde VOCs, the kinetics may be hematological or
endoluminal. Related work has recently identified characteristic
changes in the EAC phospholipid profile41, which could be
source molecules for endogenous aldehydes42. This will permit
stable isotope tracing studies to demonstrate the kinetics of
these compounds to the exhaled breath. It will also provide a
platform to explore how potential influences such as source
compound concentrations, mechanisms of production, and
microenvironmental factors contribute to the overall aldehyde
phenotype, in addition to detoxification and repair.
In summary, loss of aldehyde detoxification leads to endogenous
aldehyde accumulation in EAC, generating genotoxins and more
stable alkanals that could be a source for the same compounds
detected in the exhaled metabolite pool. Our combined analytical
and molecular approach is the first integrated investigation of tissue
aldehyde metabolism in any cancer. Further molecular studies
should seek to validate these findings, identify these compounds’
parent metabolites, trace the kinetics to the breath, and establish
whether endogenous aldehydes contribute to other upper gastro-
intestinal malignancies. In addition, these data also support the
continued clinical investigation of exhaled aldehydes for EAC early
diagnosis.
Methods
Patients. Fresh human material and associated clinical metadata was collected and
accessed under UK National Research Ethics Service Ref: 14/LO/0742, Imperial
College Healthcare Tissuebank Review Board Approvals R14067, R14087, and
R16018. Archived paraffin embedded tissue was accessed under 14/LO/0742,
approval R14067, and through 10/H0305/1. Written informed consent was taken
from all patients.
Patients were identified via the North West London Oesophago-gastric (OG)
Cancer Unit (St. Marys’ Hospital, Paddington, London, UK) and associated
endoscopy department. Tissue samples were collected at endoscopy using 3 mm
biopsy forceps thoroughly cleaned in UPLC-grade water. Typically 4–6 biopsies
were harvested at 2 cm intervals per tissue type, separated circumferentially, to
capture clonal diversity. EAC samples were collected from Siewert 1 or 2 EAC cases
that had been confirmed histologically. Tumor-adjacent normal squamous (SqT)
samples were collected 5 cm proximal to the proximal extent of the EAC or
associated Barrett’s, whichever was higher. Normal esophageal samples (SqN) were
collected 5 cm proximal to the gastro-esophageal junction in control subjects
without endoscopic abnormalities; prior or current diagnosis of cancer; active
infection, or previous esophago-gastric surgery (e.g. gastric bypass). No restriction
was placed on history of heartburn, proton pump inhibitor use, and alcohol and
tobacco use. Biopsies were flash frozen in liquid nitrogen and stored at −80 °C.
Matched biopsies were taken from all tissue sites for histopathologic confirmation.
Biopsies were flank cryosectioned and checked histologically prior to
homogenization (cellularity > 95%), if permissible by the methodology. All patients
were starved for at least 6 h prior to sampling. Demographic details were compiled
prospectively and listed in Supplementary Data 1.
Cell lines and treatments. Supplementary Data 1 lists the materials used in the
study. Commercial EAC cell lines were acquired from European Collection of
Authenticated Cell Cultures (via Public Health England) or the American Type
Culture Collection at the start of the study and cultured according to instruc-
tions. Primary keratinocyte cultures were established using a rho-kinase method
developed for skin keratinocytes16. Briefly, three endoscopic biopsies from
patients with normal endoscopic appearances were pooled and minced in serum
free Dulbecco’s modified Eagle’s media (DMEM; ThermoLife) containing gen-
tamicin/amphotericin (Invitrogen). The homogenate was incubated in col-
lagenase III (Sigma) for an hour at 37 °C, neutralized in DMEM containing 10%
FBS and the antibiotics, and forced through a 100 μm mesh. The cells were
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moved to fresh complete DMEM containing 10 μM Y-27632 (Sigma), and seeded
onto plates coated with 0.01 μg/mL bovine fibronectin and bovine albumin and
0.03 μg/mL rat tail collagen (all Sigma), in the presence of irradiated 3T3-J2
feeder cells. Lines were continually passaged for 6 weeks and checked for
mycoplasma twice prior to experiments. Y-27632 and feeder cells were with-
drawn 2weeks before experiments and fibroblast contamination was checked by
immunoblotting for vimentin. Hypoxia experiments were conducted in a
nitrogen incubator using otherwise standard culture conditions. All lines had a
passage limit of 20 and were tested for mycoplasma monthly.
Diethylaminobenzaldehyde (Sigma) was dissolved in dimethylsulfoxide
(DMSO) and was incubated with cells for 72 h. The DMSO concentration was kept
constant (0.1%). RNA interference was achieved with oligofectamine (ThermoLife)
according to the manufacturer’s instructions and confirmed by immunoblotting.
The total transfected RNA was kept constant across the conditions, supplementing
with non-targeting RNA as needed. Five-day proliferation assays were in 96-well
format using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (ThermoLIfe). Reduced and oxidized glutathione levels were
calculated using a fluorescence-based kit (Promega V6611). Cells were pre-treated
with metformin (Sigma) for 48 h, including refreshed media after 24 h, and
consistent metformin concentrations maintained for the aldehyde incubation.
Concentrations for the formaldehyde and acetaldehyde challenge experiments were
selected based on literature evaluation43,44, and were within the measured
concentrations from the tissue LC-MS data in the present study. To model the
continuous production of endogenous aldehydes seen in situ, media containing
fresh dilutions of the corresponding aldehydes was refreshed twice during
incubation.
Aldehyde quantification by ultra-performance liquid chromatography tandem
mass spectrometry
General principles. Quantification of aldehydes from tissue samples used the
dinitrophenylhydrazine method45 with numerous updates. Fastidious measures
were taken to minimize environmental contamination, including working in
clean air environment, extracting DNPH (0.2 M in 70% ethanol in phosphoric
acid, Sigma) four times with hexane (1:20 v/v) immediately prior to use, scru-
pulously clean materials which were baked at 70 °C overnight, and fresh bottles
of UPLC-grade solvents were used for every run. Blank samples involving every
element of the sample preparation process were regularly tested to ensure
background was controlled and that carryover did not occur. Alternating low
and high calibration points were injected regularly to ensure consistent instru-
ment response.
Forty-two aldehydes and ketones were selected for study (as indicated in
Supplementary Data 1). The rationale for analyte selection was any of: (i) known
genotoxin, (ii) physiological metabolite, (iii) present in exhaled breath, (iv) a
specific target for ALDH isoenzymes of interest. Analytical variation was controlled
with six isotope-labeled standards (ISTDs)—C2:0-d4 (Sigma, for short-chain
alkanals), C6:0-d12 (Sigma, for medium-chain alkanals), C16:0-d5 (Santa Cruz, for
fatty alkanals), HNE-d3 (Cambridge Bioscience, for dienals), ONE-d3 (Cambridge
Bioscience, for dialdehydes), and MDA-d2 (prepared by diluting 10 μL 1,1,3,3-
tetraethoxypropane-1,3-d2 (Santa Cruz) in 10 mL of 0.1 M HCl and hydrolyzing at
100 °C for 10 min)46).
Sample preparation. For tissue, three endoscopic biopsies (9–12 mg) were homo-
genized under liquid nitrogen in a clean pestle and mortar and weighed. To this
180 μL of dry-ice-cold UPLC acetonitrile/water (50:50 v/v) containing 62.5 ng/mL
internal standards was added with a baked ceramic bead. The slurry was extracted
in a Reitsch oscillator for 60 s at −40 °C, and protein cleared by centrifugation
(20,000g, 3 min). The supernatant was derivatized with 40 μL DNPH; the pellet re-
extracted with the same volume of extraction solvent. The two extracts were
combined and derivatized for 1 h at 25 °C. The phases were separated by adding 20
mg of baked sodium chloride, followed by centrifugation at 20,000g. The organic
phase was transferred to a clean glass UPLC vial and sealed with Teflon. In vitro
aldehydes were assayed by mixing 180 μL of media with 180 μL acetonitrile con-
taining 62.5 ng/μL ISTDs, which was then centrifuged, and derivatized as above.
Protein content was measured per well by the bicinchoninic acid method (Sigma).
Sample preparation for each experiment was conducted in a continuous run on a
single day.
UPLC-MS/MS analysis. This was undertaken on a Acquity UPLC and Waters TQS
MS/MS system. A C18 Cortecs column (particle size 1.6 μm, internal pore 2.1 μm,
Waters) was used, with UPLC-grade water (A) and UPLC-grade acetonitrile (B)
(both Sigma) mobile phases. Column temperature was 40 °C, sample temperature
4 °C, and the flow rate 0.5 mL/min. Injection volume was 5 μL, under initial con-
ditions of 30% B. The ratio was changed as follows: 0.20–8 min to 40%, then 8–16
min to 95%, 19–19.1 min to 30% and held until 20 min. The source settings were as
follows: source temperature 150 °C, capillary voltage 2.5 kV, cone voltage 10 V,
cone gas flow rate 200 L/h, desolvation gas temperature 400 °C, desolvation gas
flow rate 650 L/h. A scheduled multi-reaction monitoring MS/MS method was
established (Supplementary Data 2). Each sample was prepared in 2–3 biological
replicates depending on availability, with the final result being averaged (one result
per tissue for each patient in the final analysis).
Data processing. Acquired peaks were integrated using Targetlynx (Waters,
SCN855) and manually checked. For quantitative analysis, internal standard cali-
bration curves were calculated by dividing a serially diluted mix of all unlabeled
standards by the respective ISTD (concentration 50 ng/μL, see Supplementary
Data 1). The intensities of the unknown concentrations were also divided by the
respective ISTDs, and concentrations calculated by comparing to the ISTD cali-
bration. Tissue aldehydes were normalized to sample mass (milligrams). In vitro
aldehydes were normalized to protein concentration in a parallel well as quantified
by the bicinchoninic acid method. Isomer/isobar ketones, alkanals, and dialdehydes
(e.g. acetone, propanal, glyoxal, molecular weight= 58) were unambiguously
determined on the basis of retention time, parent ion mass-to-charge (e.g. dia-
ldehydes reacting to form a di-DNPH hydrazine) and characteristic abundant
fragment ions (e.g. 163, 152, 182 for alkanals, ketones, and dialdehydes, respec-
tively). A lower limit of quantification (LLOQ) of 20 pg/mg was set, given a
minimum tissue input of 10 mg, an extraction volume of 0.2 mL, and that 1 ng/mL
was well above the limit of detection for all targets. The manually checked inte-
grations were exported to R to reformat the matrix (RStudio version 1.1.456,
RStudio, Inc., code provided in Supplementary Data 7) and complete the proces-
sing as above. All data processing was blinded.
Aldehyde quantification using proton transfer reaction time-of-flight mass
spectrometry. Measurements were conducted employing a commercial PTR-MS
instrument (PTR-TOF 1000; Ionicon Analytik GmbH, Innsbruck, Austria). Drift
tube conditions were temperature 110 °C, pressure 2.30 mbar, and voltage 350 V,
resulting in an E/N of 84 Td (1 Townsend= 10–17 V cm2). Optimal measurement
conditions were chosen based on a validated experimental workflow47. Sample inlet
flow was set to 40 sccm. During the described experiments, a series of daily quality
checks were conducted on the PTR-TOF-MS: we assessed the amounts of spurious
ions with the two ionization modes used (H3O+ and NO+), and we measured
accuracy on a benzene certified standard and fragmentation on butanal and butyric
acid. Mass resolution was checked daily and optimized whenever needed. Tissues
samples (10–20 mg) were thawed in glass 20 ml headspace vials with Teflon insert
screw-caps (ThermoLife) left to equilibrate at 25 °C for 30 min. The headspace was
sampled for 10 s at 40 mL/min with isobaric volume replacement with cylinder air.
All data analysis was carried out using PTR-MS Viewer 3.2.2.2 (Iconicon), fol-
lowing the manufacturer’s instructions. Accurate mass peaks reaching a signal-to-
noise ratio >10:1 were integrated and normalized to the total ion emission. This
procedure accounted for sample-to-sample variation in mass and surface area.
Aldehyde–nucleotide adduct quantification by ultra-performance liquid
chromatography tandem mass spectrometry. Two aldehyde adducts of purine
nucleotide were selected for quantification: 1-N6-etheno-2′-deoxyadenosine (edA),
and α-methyl-γ-hydroxy-1,N2-propano-2′-deoxyguanosine (CrodG). For tissue
samples, five endoscopic biopsies from SqN, SqT, or EAC collected and pooled.
Leukocytes were extracted from the buffy coat of 10 mL blood collected from EAC
patients. DNA clean-up was with the Gentra Puregene kit (Qiagen). Three isotope-
labeled internal standards were used at a concentration of 5 ng/mL:
deoxyadenosine-N135 (Cambridge Isotopes), 1-N6-etheno-2′-deoxyadenosine-N135
(produced by reacting chloroacetadlehyde with deoxyadenosine-N135)48, and α-
methyl-γ-hydroxy-1,N2-propano-2′-deoxyguanosine-13C,15N2 (Toronto Research
Chemicals). UPLC-MS/MS and data processing were as previously described19.
Bioinformatics. Two datasets, GSE26886 and GSE13898 were found on Arrar-
yExpress and Gene Expression Omnibus reporting esophageal squamous mucosa
and EAC transcriptomes and were included in geneset enrichment analysis (Broad
Institute, MIT, Cambridge, MA, USA)49. The default settings and the Gene
Ontology geneset set (version 4.0) were selected for the analysis. GSE26886 used
laser capture microdissection for tissue isolation and was thus selected for pre-
sentation in Fig. 2. To identify candidate genes in the aldehyde oxidoreductase
geneset, a univariate analysis of the datasets was conducting by comparing groups
with a Student’s t-test, using a Bonferroni significance threshold of P= 10−6.
GSE26886 was also selected for Ingenuity Pathway Analysis (Core Analysis, Qia-
gen) using standard settings.
Legacy data from The Cancer Genome Atlas (available at https://portal.gdc.
cancer.gov/projects/TCGA-ESCA) and the International Cancer Genome
Consortium ICGC (available at https://ega-archive.org/studies/EGAS00001000725)
were analyzed for ALDH3A2 regulatory hypotheses (last date accessed: 1 June
2019). TCGA-ESCA data are a mixed of EAC and squamous cell cancers, and so
EAC cases (n= 87) were selected in these analyses, and a subset of these had
survival data (n= 57). ICGC data from OCCAMS were limited to 85 cases that had
a predicted normal-cell contamination <50%. For each case germline SNPs and
indels were called using the GATK (3.2-2) HaplotypeCaller, and reads supporting
each allele at germline heterozygous positions were counted for both the tumor and
matched normal. Copy number alterations along with ploidy and purity estimates
were then derived from these read counts using ASCAT (2.3), and compared to
matched RNA-seq expression data.
mRNA quantification. MIQE guidelines were adhered to for all polymerase chain
reaction (PCR) experiments50. For in vivo ALDH expression analyses, a sample size
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was determined from GSE26886 expression distributions, taking α= 0.05 and β=
0.8, which returned 5 (ALDH4A1) to 67 (ALDH1A1) paired samples. Endoscopic
tissue biopsies were flank cryosectioned and microdissected if necessary to achieve
a cell purity >90%. Homogenization was in Trizol (ThermoLIfe) using three-step
homogenization (manual pestle grinding for 2 min, ceramic bead-beating for 3
min, and then Qiashredder (Qiagen)). RNA was fractionated and then purified
(RNAeasy, Qiagen). Reverse transcription was with Superscript III kit (Thermo-
LIfe), and quantitative PCR using PowerSybr PCR master mix (ThermoLife).
Primers were designed in Primer3 (see Supplementary Data 6). The MIQE-
suggested panel of 10 reference genes was assayed in a panel of 10 random samples
and HPRT1 was found to be the most stable. All data processing was blinded.
Immunohistochemistry. We collated tissue microarrays or whole-mount sections
from 571 EAC patients from Imperial College Healthcare NHS Trust tissuebank
and national collaborative resources (the OCCAMS and POEM collaborations, see
“Acknowledgements”). The Leica Bond™ system was used. Sections (7 μm) were
deparaffinized, hydrated, and then heat mediated antigen retrieval was performed
in citrate-based pH 6.0 solution for ALDH3A1 staining and EDTA based
pH9.0 solution for ALDH3A2. The endogenous peroxidase was quenched with 3%
hydrogen peroxide. The sections were incubated ALDH3A1 antibody (1:200
dilution) or ALDH3A2 antibody (1:200 dilution) and subsequently incubated with
anti-rabbit IgG conjugated with polymeric horseradish peroxidase linker (Leica
Bond Polymer Refine Detection, DS9800). DAB was used as the chromogen and
the sections were then counterstained with hematoxylin and mounted with DPX.
Antibodies were as for immunoblotting and details are provided in the Supple-
mentary Data 1.
Sections were imaged (NanoZoomer 2.0HT, Hamamatsu). Scoring was by two
pathologists who were blinded to the metadata. For whole-mount sections SqT,
BAR, and EAC regions were scored in five random high-powered areas according
0–3 on a basis of staining intensity and prevalence (0= no staining or <50% mild
staining; 1 ≥ 50% mild staining, no moderate staining; 2= any moderate staining,
<50% strong staining; 3 ≥ 50% strong staining)51 with a single average score per
tissue type per patient used for comparative analysis. For correlation to metadata,
the immunoscore was dichotomized, with a cut-off of >1 being positive. For tissue
microarrays, replicate cores for each patient were provided in quintuplet (Imperial
array) or triplicate (OCCAMS and POEM arrays, see “Acknowledgements”).
Averaging across scorers and replicates generated a single score per patient.
Immunoblotting. Protein samples (30 μg) were separated by SDS-PAGE and
transferred to PVDF membranes (all Biorad). Blots were probed with antibodies
listed in Supplementary Data 1. The following antibody dilutions were used for
immunoblotting: ALDH1A3 1:333, ALDH3A1 1:500, ALDH3A2 1:333, ALDH4A1
1:2000, ALDH9A1 1:500, Tubulin 1:2000, Cyclophilin B 1:1000, E-cadherin 1:1000,
CK5/6 1:2000, p63 1:2000, Phospho-Histone H2AX (Ser139) 1:1000, TP53 1:2000,
Vimentin 1:2000, Phospho-ATM (Ser1981) 1:1000, Phospho-ATR (Ser428) 1:1000,
Phospho-CHK1 (Ser345) 1:1000, and Phospho-CHK2 (Thr68) 1:1000.
Fluorescence in situ hybridization. The following BACs were used as probes for
the FISH experiments: RP11-227J24, containing alpha satellite specific for the
centromere of chromosome 17; RP11-352K5 (hg19 17:19,532,515–19,692,855,
ALDH3A1 and -3A2 (SourceBioscience); RP11-89D11 (hg19 17:7,495,711-
7,663,042, TP53 (SourceBioscience). The BACs were labeled according to the
manufacturer’ instructions, using the Nick Translation System kit (Abbott Mole-
cular), incorporating ChromaTide Alexa Fluor 488-5-dUTP (Thermo Fisher Sci-
entific), ChromaTide Alexa Fluor 594-5-dUTP (Thermo Fisher Scientific), or
biotin-16-dUTP (Sigma), respectively. The probes were re-suspended in hybridi-
zation buffer (50% formamide, 10% dextran sulfate, 2× SSC) at 10 ng/μL, in the
presence of a 10× excess of unlabeled human Cot DNA (Sigma).
The triplicate TMAs from the Bristol and Oxford OCCAMS cohorts were used
as their local fixing process generated minimal background fluorescence. The slides
were dewaxed and hydrated in xylene and ethanol respectively. Heat-induced
epitope retrieval was in TE buffer, at 95 °C, for 15 min, then briefly equilibrated in
distilled water at room temperature. Protein digestion was carried out at 37 °C,
using Digest All-3 pepsin (Thermo Fisher Scientific). The cells were briefly de-
hydrated in ethanol 96%, and then 20 μL of probe mix were applied to the slides,
under a glass coverslip. Following denaturation at 85 °C for 5 min, the cells were
incubated overnight at 37 °C. Post-hybridization washes were carried out at 60 °C
in 0.1× SSC. The biotinylated probe was detected using streptavidin-647 (Thermo
Fisher Scientific). The Papworth and Glasgow arrays were not included in the
analysis as the DNA binding sites could not be retrieved, presumably through
differences in the original histological preparation.
The slides were mounted in DAPI/Vectashield (Oncor), and analyzed using the
Delta Vision Elite Imaging System. For each core, 2–3 high cellularity (>95%
adenocarcinoma) fields were acquired as 35 × 0.2 μm z-stacks, and the resulting
images were deconvolved. The stacks were compressed using the z-projection
function in Fiji (Fiji Is Just Imagej)52, generating average projection images (DAPI)
and max projection images (for the three colors). A fully automated image analysis
method was constructed in Cell Profiler (Broad Institute). Masks were generated
using the DAPI image, selecting nuclei on size and roundness to filter out non-
malignant cells, improving cellularity to >99% (average of 20 images, manual
counting). The average counts per mask were calculated for each probe, and
typically 300–500 masks were counted per field. Target probes count (ALDH3A1/2
and TP53) were presented as a function of the control probe count
(centromere 17).
Quantification and statistical analysis. Calculations for bench experiments were
conducted in Metaboanalyst 4.0 (https://www.metaboanalyst.ca/), Prism (version 7.0),
SPSS (version 26) or R. For principal component analysis, measured aldehyde con-
centrations were adjusted by weight, and then mean-centered and log-transformed to
normalize the data and give each feature equal weight in the model. Prism or GENE-E
(Broad Institute) was used to visualize metabolic data as heatmaps. All experimental
groups showed similar variances. Mann–Whitney U-test or one-way ANOVA with
Bonferroni correction was used to compare groups, *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001. Further details are provided in the figure legends.
For the multivariable diagnostic model based on tissue aldehyde concentrations,
we applied our previous regression-based methodology to select features6. Briefly, a
binary logistic regression model was fitted, using squamous samples from healthy
patients (SqN) as the control group, and any sample from the malignant esophagus
as the test group (SqT, EAC, BAR). A stepwise approach was used to add
significant features until the model could no longer be improved. These analyses
were conducted in SPSS. Metabolites contributing to the final model were then
used to create a multivariable ROC curve using the Random Forests approach,
using the Biomarker package of Metaboanalyst.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Legacy microarray expression studies re-analyzed here (in Fig. 1 and Supplementary
Fig. 1) are available at https://www.ncbi.nlm.nih.gov/gds, under the accession codes:
GSE26886, GSE13898, GSE39491) and GSE34619. Data from The Cancer Genome Atlas
(used in Fig. 5 and Supplementary Fig. 6) is available at https://portal.gdc.cancer.gov/
projects/TCGA-ESCA. Data from the International Cancer Genome Consortium (used
in Supplementary Fig. 6) is available at https://ega-archive.org/studies/
EGAS00001000725. Data from The Cancer Cell Line Encyclopedia (used in
Supplementary Fig. 6) is available at https://portals.broadinstitute.org/ccle. Source data
are provided with this paper.
Code availability
The code pertaining to the transfer of Targetlynx peak integrations to R is provided in
Supplementary Data 7.
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